Literature DB >> 32273707

The Occurrence and Longitudinal Changes of Cognitive Impairment After Acute Ischemic Stroke.

Xiao-Ling Liao1, Li-Jun Zuo1, Ning Zhang2, Yang Yang2, Yue-Song Pan3, Xiang-Long Xiang3, Ling-Yun Chen4, Xia Meng3, Hao Li3, Xing-Quan Zhao1, Yi-Long Wang1, Chun-Xue Wang2, Jiong Shi3, Yong-Jun Wang1.   

Abstract

BACKGROUND AND
PURPOSE: More and more evidence suggests that cognitive impairment (CI) after stroke is closely related to the quality of life of stroke patients. The primary aim of this study is to investigate the occurrence and longitudinal changes of CI at different stages after acute ischemic stroke (AIS) in Chinese patients.
METHODS: The data of this study come from the impairment of cognition and Sleep after acute ischemic stroke or transient ischemic attack in Chinese patients study (ICONS), a nationwide multicenter prospective registry that recruited consecutive AIS or transient ischemic attack in-hospital patients within 7 days after onset. Patients were followed for Montreal Cognitive Assessment (MoCA) scale at 2-week (2w), 3 months (3m) and 12 months (12m). CI was defined as MoCA score≦22. No cognitive impairment (NCI) was defined as MoCA score>22.
RESULTS: A total of 2432 AIS patients were enrolled in this study. Overall, 72.94% of patients were male and the average age was 60.95 years. Median National Institutes of Health Stroke Scale score was 3. The occurrence rate of CI was 52.38%, 35.55% and 34.16% at 2w, 3m and 12m. Among patients with CI at 2w and 3m, 39.9% and 27.9% of patients returned to NCI at next follow-up point. At 3m and 12m follow-up, there were also 9.6% and 12.7% new CI patients. The two cognitive items with the highest abnormal rate were "Delayed recall" (89.35%, 83.33% and 82.80%) and "Visuospatial/executive" (78.91%, 73.42% and 70.08%). The cognitive item with the highest percentage of improved patients was "Orientation" (60.91-76.68%), and the cognitive item with the lowest percentage of improved patients was "Language" (35.85-44.50%).
CONCLUSION: CI had a relatively high occurrence at 2w to 12m after AIS. CI at 3m and 12m was significantly lower than that at 2w after stroke. The occurrence of abnormalities and recovery probability for different cognitive items also differed greatly.
© 2020 Liao et al.

Entities:  

Keywords:  cognitive impairment; ischemic stroke; longitudinal cohort study; occurrence

Year:  2020        PMID: 32273707      PMCID: PMC7114937          DOI: 10.2147/NDT.S234544

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

Stroke is the second leading cause of death worldwide and the leading cause of mortality and disability in China.1,2 Research and interventions have historically mainly focused on physical disabilities, but more and more evidence suggests that cognitive impairment (CI) is closely related to the prognosis of stroke patients.3–5 Post-stroke cognitive impairment (PSCI) may reduce the quality of life, and increase the risk of stroke recurrence.6 It cast a heavy economic burden to families and the society. PSCI has gained more attention in current stroke research and intervention internationally. In American Heart Association (AHA)/American Stroke Association (ASA) 2016 guidelines for adult stroke rehabilitation and recovery, screening for cognitive deficits is recommended for all stroke patients before discharge.7 Stroke burden in China has increased over the past 30 years. There are 7 million stroke patients in China. The age-standardized occurrence is 246.8/100 000 person-years.8,9 However, the public awareness of CI after stroke is low in China. There is currently no nationwide multi-center survey of CI in acute stroke patients in China, except data from local cities. The primary aim of this study is to investigate the occurrence and longitudinal changes of CI at different stages after acute ischemic stroke (AIS) in Chinese patients.

Methods

Overview of the Study

The data of this study come from the Impairment of CognitiON and Sleep after acute ischemic stroke or transient ischemic attack in Chinese patients (ICONS) study. In this manuscript, we analyzed the occurrence and longitudinal changes of CI after AIS. ICONS is one of the research subgroups of China National Stroke Registry-III (CNSR-III).10 CNSR-III is a nationwide prospective registry for consecutive patients presented to hospitals within 7 days after AIS or transient ischemic attack (TIA) between August 2015 and March 2018 in China. The protocol of the CNSR-III study was approved by ethics committee at Beijing Tiantan Hospital. Written informed consent was obtained from all patients or his/her representatives before being entered into the study. The study sites with the experience of cognition and sleep research among CNSR-III were selected to participate in the ICONS study. Among the patients of CNSR-III who met the sub-group inclusion criteria were selected and included in ICONS. The main aims of ICONS are to investigate the occurrence and the influencing factors of CI and sleep disorder at 2-week (2w), 3-month (3m), and 12-month (12m) after AIS/TIA in Chinese patients. The protocol of the ICONS study was also approved by ethics committee at Beijing Tiantan Hospital and all participating centers. Separate written informed consent was also obtained. Both studies were conducted in accordance with the Declaration of Helsinki.

Site Selection

The project of ICONS was carried out in multiple hospitals and medical centers. The steering committee hospitals nationwide to represent the population from each region of East, West, South, North, Center of Mainland China. 52 hospitals were invited initially, 46 agreed, and 40 were ultimately selected by the ICONS steering committee based on their research capability and commitment to the study. Figure 1 presents the geographical locations of these 40 participating hospitals.
Figure 1

The geographical locations of participating hospitals in the ICONS.

The geographical locations of participating hospitals in the ICONS.

Patient Enrollment and Definition of CI

The ICONS study recruited consecutive patients from August 2015 to January 2018 who met the following criteria:

Inclusion Criteria

Age ≥18 years old; Diagnosis of AIS/TIA; Admission within 7 days after onset of AIS/TIA. Ability to understand, confirm and sign the informed consent.

Exclusion Criteria

Silent cerebral infarction diagnosed by MRI or CT without symptoms and signs. Illiterate patients. History of cognitive impairment, psychosis or schizophrenia disease (documented in medical records). Other factors that interfere with cognitive or sleep evaluation, e.g. severe aphasia defined as National Institutes of Health Stroke Scale (NIHSS) item 9(Best Language)>2, consciousness disorders defined as NIHSS item 1a (Level of Consciousness)>1 or 1b (LOC Questions)>1, hearing loss, visual impairment, hard to cooperate, severe unilateral neglect or dyslexia. Unable to complete the baseline Montreal Cognitive Assessment (MoCA) and other tests. Acute ischaemic stroke and TIA were diagnosed according to the WHO criteria (acute onset of neurological deficit, persisting for >24hours in case of stroke, or for <24hours in case of TIA) and confirmed by MRI or brain CT (If with evidence of associated acute focal infarction on imaging, the patient will be diagnosed as a stroke rather than a TIA, even if neurological deficit persisting for <24hours).11,12 Considering the difference in duration of symptoms and infarction between TIA and AIS patients, the cognitive abnormalities of them will be different. In this study, we only choose the AIS population for analysis. In this study, CI was defined as MoCA≦22. No cognitive impairment (NCI) was defined as MoCA score>22. Regarding the identification of PSCI, the best cut-off point was still be controversial.13–16 The meta-analysis by Lees et al showed that the conventional cut-off point (<26/30) had excellent sensitivity (0.95) but suboptimal specificity (0.45). By comparison, the adapted MoCA cut-off point (<22/30) improved specificity (0.78) while maintaining good sensitivity (0.84).15 Previous research by our team also found that MoCA cut-off score of 22/23 was optimally sensitive (0.85) and specific (0.88) for detecting CI after mild stroke and TIA in Chinese patients.16 The overall patients enrolled in our study may be relatively mild. So in this study, we also define CI as MoCA≦22.

Baseline/Follow-Up Data Collection and Data Management

The ICONS study baseline data and follow-up collection and processing methods were the same as the CNSR-III study.10 Patients were interviewed face-to-face at 2w, 3m and 12m and contacted over the telephone by trained research coordinators at 6m and 2–5 years annually. Based on the follow-up content of CNSR-III study. For all patients included in the ICONS study, at 2w or discharge, 3m and 12m, MoCA,13,17 Pittsburgh Sleep Quality Index (PSQI),18 Epworth Sleeping Scale (ESS),19 Patient Health Questionnaire-9 (PHQ-9),20 General Anxiety Disorder-7 (GAD-7),21 10-meter walking speed test and stroke impact scale (SIS-16) were evaluated face to face.22,23 All tests were administered with same version by trained examiners. The medications for cognitive impairment, sleep disorder and depression were also recorded. The MoCA scale is the most commonly used cognitive instrument for screening for CI in patients with mild stroke or TIA. It is a one-page 30-point test for cognition administered in about 10 mins, including Visuospatial/executive abnormal (5 points), Naming (3 points), Attention (2 points), Language (2 points), Delayed recall (5 points) Orientation (6 points).13,17 The same version of MoCA were used at all follow-up point.

Statistical Analysis

Means with standard deviation or median with the interquartile range were used for continuous variables. Proportions were used to describe the categorical variables. t-test or Mann–Whitney test was performed to compare continuous variables, while as chi-square test or fisher’s exact test was performed to compare the categorical variables. A two-sided p value <0.05 was considered to be statistically significant. All analyses were conducted with SAS 9.4 (SAS Institute Inc, Cary, NC).

Results

Patient recruitment and 12m follow-up had been completed. There were 2704 patients who were screened and consented from 40 participating sites between August 2015 and January 2018. Finally, a total of 2625 patients were eligible for ICONS study. 2432 AIS patients were included for this study. The detailed patient enrollment flow chart is shown in Figure 2.
Figure 2

Flow chart of patient enrollment in the study. There were 2704 patients who were screened and consented from 40 participating sites. Finally, a total of 2432 acute ischemic stroke patients were included for this study.

Flow chart of patient enrollment in the study. There were 2704 patients who were screened and consented from 40 participating sites. Finally, a total of 2432 acute ischemic stroke patients were included for this study. Baseline characteristics of the included AIS patients are presented in Table 1. Overall, 72.94% of patients were male and the average age was 60.95 years. The median time from disease onset to enrollment was 1 day. Median NIHSS score was 3.
Table 1

Baseline Demographic Characteristics, Medical History and Stroke Subtype

Baseline VariablesAIS n(%) N=2432
Gender male1774(72.94)
Average age (years)60.95±10.78
Race (Han)2351(96.67)
Education level
 Elementary or below638(26.23)
 Middle school867(35.65)
 High school or above809(33.26)
 Unknown118(4.85)
Current smoker890(36.60)
Secondhand smoking385(15.83)
Heavy drinker (>60g/d)154(6.33)
Medical History
  Diabetes562(23.11)
  Hypertension1530(62.91)
  Lipid metabolism disorders234(9.62)
  Cerebral infarction509(20.93)
  ICH32(1.32)
  Subarachnoid hemorrhage4(0.16)
 TIA64(2.63)
  Heart failure9(0.37)
  Atrial fibrillation72(2.96)
 Carotid artery stenosis15(0.62)
 Epilepsy7(0.29)
 Sleep Apnea29(1.19)
Median NIHSS score (IQR)3(1–5)
Stroke subtype for TOAST
 Large artery atherosclerosis1407(57.85)
 Cardiogenic embolism99(4.07)
 Small artery occlusion768(31.58)
 Other/Unknown158(6.50)
Median Stroke onset to enrollment time (day)1(0–2)

Abbreviations: ICH, Intracranial Cerebral Hemorrhage; TIA, Transient Ischemic Attack; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range; TOAST, the Trial of Org 10,172 in Acute Stroke Treatment.

Baseline Demographic Characteristics, Medical History and Stroke Subtype Abbreviations: ICH, Intracranial Cerebral Hemorrhage; TIA, Transient Ischemic Attack; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range; TOAST, the Trial of Org 10,172 in Acute Stroke Treatment. Number of completed people for face-to-face evaluation of MoCA and the occurrence rate of CI at each follow-up point is shown in Table 2. The occurrence rate of CI (defined as MoCA≦22) was 52.38%,35.55% and 34.16% at 2w, 3m and 12m. At the three follow-up time points (2w,3m and 12m), the two cognitive items with the highest abnormal rate were “Delayed recall” (89.35%, 83.33% and 82.80%) and “Visuospatial/executive” (78.91%, 73.42% and 70.08%).
Table 2

Cognitive Impairment at Different Stages After AIS

At 2 Weeks n/N (%)At 3 Months n/N (%)At 12 Months n/N (%)
MoCA&≦221274/2432(52.38)749/2107(35.55)456/1335(34.16)
MoCA&< 261841/2432(75.70)1230/2107(58.38)753/1335(56.40)
Visuospatial/executive abnormal#1905/2414(78.91)1525/2077(73.42)918/1310(70.08)
Naming abnormal#744/2428(30.64)444/2103(21.11)248/1327(18.69)
Attention abnormal#1098/2428(45.22)773/2106(36.70)445/1332(33.41)
Language abnormal#1433/2425(59.09)1173/2092(56.07)740/1324(55.89)
Abstraction abnormal#1359/2416(56.25)915/2048(44.68)562/1302(43.16)
Delayed recall abnormal#2156/2413(89.35)1714/2057(83.33)1083/1308(82.80)
Orientation abnormal#912/2426(37.59)491/2104(23.34)302/1334(22.64)

Notes: &MoCA indicates Montreal Cognitive Assessment. #“abnormal” is defined as the total score of this cognitive item in MoCA scale is deducted by 1 point and above.

Cognitive Impairment at Different Stages After AIS Notes: &MoCA indicates Montreal Cognitive Assessment. #“abnormal” is defined as the total score of this cognitive item in MoCA scale is deducted by 1 point and above. Figure 3 details the longitudinal changes of CI (defined as MoCA≦22) at each follow-up point. Among patients with CI at 2w and completed MoCA follow-up at 3m, 39.9% (433/1084) of patients returned to NCI at 3m follow-up. And among patients with CI at 3m and completed MoCA follow-up at 12m, 27.9% (127/456) patients returned to NCI at 12m follow-up. At 3m and 12m follow-up, there were also 9.6% (98/1023) and 12.7% (105/828) new CI patients.
Figure 3

The longitudinal changes of cognitive impairment at each follow-up point. The figure showed the longitudinal changes of cognitive impairment at each follow-up point. This included the number of patients who actually completed the follow-up evaluation of the scale and their proportion. The number of unfinished follow-ups was not shown in the figure.

Abbreviations: CI, cognitive impairment; NCI, no cognitive impairment.

The longitudinal changes of cognitive impairment at each follow-up point. The figure showed the longitudinal changes of cognitive impairment at each follow-up point. This included the number of patients who actually completed the follow-up evaluation of the scale and their proportion. The number of unfinished follow-ups was not shown in the figure. Abbreviations: CI, cognitive impairment; NCI, no cognitive impairment. Table 3 shows the percentage of improved patients for each abnormal cognitive item in MoCA scale at 3m and 12m follow-up compared with those at 2w or 3m. The cognitive item with the highest percentage of improved patients was “Orientation” (60.91–76.68%), and the cognitive item with the lowest percentage of improved patients was “Language” (35.85–44.50%).
Table 3

The Percentage of Improved Patients for Each Abnormal Cognitive Item in MoCA Scale at 3-Month (3m) and 12-Month (12m) Follow-Up

Improved& n/N# (%) (at 3m vs at 2w)Improved& n/N# (%) (at 12m vs at 2w)Improved& n/N# (%) (at 12m vs at 3m)
Visuospatial/executive735/1609(45.68)500/1010(49.50)308/908(33.92)
Naming387/643(60.19)270/406(66.50)127/266(47.24)
Attention559/941(59.40)414/600(69.00)251/452(55.53)
Language461/1204(38.29)340/764(44.50)252/703(35.85)
Abstraction519/1125(46.13)393/714(55.04)172/519(33.14)
Delayed recall954/1814(52.59)691/1166(59.26)387/1028(37.65)
Orientation573/775(73.94)388/506(76.68)187/307(60.91)

Notes: &“Improved” is defined as “the total score of this cognitive item is abnormal at 2w or 3m, but increased by 1 point and above at a later time point (3m or 12m)”. #N= the total number of patients who were abnormal at an earlier time point (2w or 3m) and completed follow-up at a later time point (3m or 12m). #n=Among N, the number of patients who were improved at a later time point (3m or 12m).

The Percentage of Improved Patients for Each Abnormal Cognitive Item in MoCA Scale at 3-Month (3m) and 12-Month (12m) Follow-Up Notes: &“Improved” is defined as “the total score of this cognitive item is abnormal at 2w or 3m, but increased by 1 point and above at a later time point (3m or 12m)”. #N= the total number of patients who were abnormal at an earlier time point (2w or 3m) and completed follow-up at a later time point (3m or 12m). #n=Among N, the number of patients who were improved at a later time point (3m or 12m).

Discussion

ICONS is the first prospective national registry study for cognitive impairment and sleep disorders on AIS and TIA in an inpatient population in China. In this manuscript, we mainly introduced the overall protocol of ICONS and analyzed the occurrence and longitudinal changes of CI after AIS. The occurrence of CI after stroke in previous studies varies greatly depending on the region, ethnicity, diagnostic criteria, stroke severity, assessing time after stroke, and the method of assessment. The MoCA and the Mini-Mental State Examination (MMSE) were commonly recommended tools for screening for CI. They include relatively good global cognitive assessment and the operation is relatively simple. In European countries, using the MMSE or MoCA, the occurrence of CI at 3 months after stroke was 24% to 47%.24,25 However, using comprehensive neuropsychological tests which is more comprehensive and accurate for cognitive function evaluation, the occurrence of CI in the same population may be higher (96% vs 39%).25 In Asia, a multicenter, cohort study in Korea that enrolled 620 patients with ischemic stroke and used MMSE assessment showed that the occurrence of CI was as high as 69.8% at 3 months after stroke.26 In China, a study of ischemic stroke patients in Chongqing city, using MMSE assessment, the occurrence of CI after 3 months of stroke was 32.2%.27 Most of the reported PSCI studies only followed patients up to 3 months after stroke. Since cognitive decline is usually a long-term process, a longer follow-up period is warranted. The ICONS study was the first prospective national registry study for CI after AIS and TIA in an inpatient population in China. Compared with previous studies, ICONS study has more frequent and longer follow-ups. According to the inclusion criteria of this study, some of more severe populations were not selected in this study because of the difficulty in accurately evaluating MoCA. Therefore, the selected population in this study was actually younger and milder than the typical stroke population, but the results showed that there was still a relatively high occurrence of CI. This suggests that we really should give enough attention to CI after AIS. Baseline data showed that the overall patients enrolled in our study were mild. The median NIHSS score for AIS population was only 3 points. It showed that even in mild stroke, CI was a frequent consequence. And it may often masked and does not fully manifest until after acute hospitalization. So we should recommend standardized cognitive screening even in patients with mild stroke. The study also showed that the occurrence of CI at 3m and 12m after stroke was significantly lower than that at 2w after stroke, suggesting that CI after stroke, especially early CI was partially recoverable. Yet, indeed, for the identification of CI, the best cut-off point is still controversial. Nevertheless, MoCA or MMSE score below a cut-point is not the only accepted criteria for the Diagnosis of CI or even dementia. In this study, we defined CI as MoCA≦22. This is a relatively strict definition. If calculated in terms of cognitive decline (eg MoCA<26), the proportion of abnormalities will be much higher. Cognitive decline that not severe enough to diagnose CI should also cause our attention.28,29 This study further confirmed that CI could occur both immediately after stroke and after a delay. The CI at different periods may have different pathogenesis, clinical features and prognosis.30 PSCI is a complex syndrome, suggesting that our future research direction should be more accurately classify people with CI after stroke in order to find a better therapeutic target. This study also analyzed the occurrence of abnormalities and recovery probability for different cognitive items. The results showed that the most easily improved cognitive item was “Orientation”, and the most difficultly improved cognitive item was “Language”. This also helps us to more accurately understand the prognosis of different CI symptoms, and guide the subsequent evaluation focus and rehabilitation direction. There are several limitations of our study. First, limited by the financial and human resources, we did not use a full neuropsychological battery which is more comprehensive and accurate for cognitive function evaluation. In addition to the MoCA scale, if additional assessments could be supplemented, it may offer further insight into problem areas. Second, although the overall sample size of the study was relatively large, the follow-up completion rate for 12m was not very high. This will cause a sampling bias and have an impact on the relevant conclusions at this follow-up point. Third, as a national registry study, although we had selected 40 centers from different regions, we did not cover all provinces of China.

Conclusion

CI had a relatively high occurrence at 2w to 12m after AIS. CI at 3m and 12m was significantly lower than that at 2w after stroke. The occurrence of abnormalities and recovery probability for different cognitive items also differed greatly.
  30 in total

Review 1.  Cognitive and mood assessment in stroke research: focused review of contemporary studies.

Authors:  Rosalind Lees; Patricia Fearon; Jennifer K Harrison; Niall M Broomfield; Terence J Quinn
Journal:  Stroke       Date:  2012-04-24       Impact factor: 7.914

2.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

3.  Stroke and Cognitive Decline.

Authors:  Philip B Gorelick; David Nyenhuis
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

4.  What are the correlates of cognition and participation to return to work after first ever mild stroke?

Authors:  Y Fride; T Adamit; A Maeir; E Ben Assayag; N M Bornstein; A D Korczyn; N Katz
Journal:  Top Stroke Rehabil       Date:  2015-10       Impact factor: 2.119

5.  Cognitive Impairment, Vulnerability, and Mortality Post Ischemic Stroke: A Five-Year Follow-Up of the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) Cohort.

Authors:  Eva Gaynor; Daniela Rohde; Margaret Large; Lisa Mellon; Patricia Hall; Linda Brewer; Orla Conway; Anne Hickey; Kathleen Bennett; Eamon Dolan; Elizabeth Callaly; David Williams
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-05-24       Impact factor: 2.136

6.  Predictive value of MoCA in the acute phase of stroke on the diagnosis of mid-term cognitive impairment.

Authors:  Emilia Salvadori; Marco Pasi; Anna Poggesi; Guido Chiti; Domenico Inzitari; Leonardo Pantoni
Journal:  J Neurol       Date:  2013-05-29       Impact factor: 4.849

7.  Post-stroke cognitive impairment: high prevalence and determining factors in a cohort of mild stroke.

Authors:  Agnès Jacquin; Christine Binquet; Olivier Rouaud; Anny Graule-Petot; Benoit Daubail; Guy-Victor Osseby; Claire Bonithon-Kopp; Maurice Giroud; Yannick Béjot
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

8.  The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.

Authors:  D J Buysse; C F Reynolds; T H Monk; S R Berman; D J Kupfer
Journal:  Psychiatry Res       Date:  1989-05       Impact factor: 3.222

9.  Poststroke Cognitive Decline: A Longitudinal Study from a Tertiary Care Center.

Authors:  Rameshwar Nath Chaurasia; Jitendra Sharma; Abhishek Pathak; Vijay Nath Mishra; Deepika Joshi
Journal:  J Neurosci Rural Pract       Date:  2019-10-07

10.  The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics.

Authors:  Yongjun Wang; Jing Jing; Xia Meng; Yuesong Pan; Yilong Wang; Xingquan Zhao; Jinxi Lin; Wei Li; Yong Jiang; Zixiao Li; Xinmiao Zhang; Xiaomeng Yang; Ruijun Ji; Chunjuan Wang; Zhimin Wang; Xinsheng Han; Songdi Wu; Zhengchang Jia; Yongming Chen; Hao Li
Journal:  Stroke Vasc Neurol       Date:  2019-06-29
View more
  9 in total

1.  Impact of Persistent Poor Sleep Quality on Post-Stroke Anxiety and Depression: A National Prospective Clinical Registry Study.

Authors:  Xiao-Wei Fan; Yang Yang; Shuo Wang; Yi-Jun Zhang; An-Xin Wang; Xiao-Ling Liao; Wei-Guo Ma; Ning Zhang; Chun-Xue Wang; Yong-Jun Wang
Journal:  Nat Sci Sleep       Date:  2022-06-13

Review 2.  Information provision for stroke survivors and their carers.

Authors:  Thomas F Crocker; Lesley Brown; Natalie Lam; Faye Wray; Peter Knapp; Anne Forster
Journal:  Cochrane Database Syst Rev       Date:  2021-11-23

3.  Usability and Acceptability of a Novel Secondary Prevention Initiative Targeting Physical Activity for Individuals after a Transient Ischaemic Attack or "Minor" Stroke: A Qualitative Study.

Authors:  Neil Heron; Sean R O'Connor; Frank Kee; Jonathan Mant; Margaret E Cupples; Michael Donnelly
Journal:  Int J Environ Res Public Health       Date:  2020-11-26       Impact factor: 3.390

4.  Effects of different acupuncture treatment methods on post-stroke cognitive impairment: study protocol for a multicenter randomized controlled trial.

Authors:  Kai-Qi Su; Su-Tong Liu; Jie-Ying Li; Rui-Qing Li; Hui-Li Feng; Yang Xue; Xiao-Dong Feng
Journal:  Trials       Date:  2021-01-06       Impact factor: 2.279

5.  Impact of Sleep Duration on Depression and Anxiety After Acute Ischemic Stroke.

Authors:  Fei Liu; Yang Yang; Shuo Wang; Xiao-Li Zhang; An-Xin Wang; Xiao-Ling Liao; Hong-Juan Fang; Yue Qu; Wei-Guo Ma; Ning Zhang; Chun-Xue Wang; Yong-Jun Wang
Journal:  Front Neurol       Date:  2021-03-26       Impact factor: 4.003

6.  Gamma-glutamyl transferase levels are associated with the occurrence of post-stroke cognitive impairment: a multicenter cohort study.

Authors:  Siqi Li; Xiaoling Liao; Yuesong Pan; Xianglong Xiang; Yumei Zhang
Journal:  BMC Neurol       Date:  2022-02-23       Impact factor: 2.474

7.  Development of a Digital Lifestyle Modification Intervention for Use after Transient Ischaemic Attack or Minor Stroke: A Person-Based Approach.

Authors:  Neil Heron; Seán R O'Connor; Frank Kee; David R Thompson; Neil Anderson; David Cutting; Margaret E Cupples; Michael Donnelly
Journal:  Int J Environ Res Public Health       Date:  2021-05-02       Impact factor: 3.390

Review 8.  A review of the quality and content of mobile apps to support lifestyle modifications following a transient ischaemic attack or 'minor' stroke.

Authors:  Seán R O'Connor; Frank Kee; David R Thompson; Margaret E Cupples; Michael Donnelly; Neil Heron
Journal:  Digit Health       Date:  2021-12-15

9.  Effects of an Eye-Tracking Linkage Attention Training System on Cognitive Function Compared to Conventional Computerized Cognitive Training System in Patients with Stroke.

Authors:  Sung-Jun Moon; Chan-Hee Park; Sang In Jung; Ja-Won Yu; Eun-Chul Son; Hye Na Lee; Hyeonggi Jeong; Sueun Jang; Eunhee Park; Tae-Du Jung
Journal:  Healthcare (Basel)       Date:  2022-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.